The Protocol-Only Coverage Analysis: What a Site Can Defend Before the Budget Arrives

THE BILLING GRID
A weekly column on research billing and coverage analysis, by Krishma Shah

The budget has not arrived. The contract is somewhere in legal. The sponsor is asking whether your site can activate in 45 days. And your compliance officer wants a coverage analysis before anyone touches a patient. This is the feasibility moment that exposes how well a site actually understands research billing, because the tool you need is a protocol-only Medical Coverage Analysis, and most sites either skip it or do it wrong.

A Medical Coverage Analysis, or MCA, is the document that maps every protocol-required procedure to one of three designations: standard of care (SOC, meaning the procedure is billable to Medicare or a commercial insurer when the trial qualifies), research-paid (RES, meaning the sponsor owns the cost), or non-billable and invoiceable (NB/INV, meaning the item appears in the site budget as a line to be negotiated). The MCA is not a budget. It is the coverage logic that tells you whether a charge can legally touch a patient’s insurance at all.

At feasibility, you do not have a budget, but you do have a protocol. A protocol-scoped MCA uses that protocol alone to build the visit-grid designations for every procedure at every visit. The result is a defensible first-pass map of coverage logic. It is a real deliverable, not a placeholder, and it belongs on the site-activation critical path alongside the IRB submission and the clinical trial agreement, because the billing team cannot set up the charge router without it.

What the Defensible Protocol-Only MCA Can Say

The core unit of defensibility in any MCA is the visit-grid cell: the intersection of a specific procedure and a specific visit. The same blood draw can be SOC at the screening visit and RES at a mid-cycle safety visit, depending on what the protocol requires versus what routine clinical care would require for this patient population. A protocol-only MCA can assign designations at the cell level for every procedure the protocol specifies, because the protocol is the source of truth for what is research-required versus what would happen in standard practice regardless of trial participation.

Coverage citations are the other thing a protocol-only MCA can do correctly. If the protocol requires a complete blood count at every visit, the MCA should cite NCD 190.15, the National Coverage Determination that governs laboratory diagnostic services including CBCs. Writing “routine labs” with no citation is the single most common audit weak point in MCAs reviewed across site networks. The citation is not a formality; it is the evidence that ties your SOC designation to an actual Medicare coverage rule. A protocol-only MCA can and should include those citations, because they come from the procedure type, not from the budget or the charge master.

Qualifying trial status is another element the protocol-only MCA can address. NCD 310.1 governs routine cost coverage in qualifying clinical trials. A trial qualifies when it is conducted under an Investigational New Drug application and meets the therapeutic intent and Medicare benefit category criteria that NCD 310.1 requires. The protocol tells you whether the trial is IND-governed and whether the intervention is therapeutic. The MCA can flag deemed status at feasibility so the billing team knows which visits can route SOC charges to Medicare at all.

What the Protocol-Only MCA Cannot Finalize

The INVOICEABLE section of the MCA is where the protocol-only version hits its limit. The NB/INV designation means an item is not billable to insurance and must appear as a negotiated line in the sponsor budget. Pricing those lines requires the charge master, and you do not have it in a protocol-only pass. The budget reconciliation step, which happens when the sponsor’s proposed budget arrives, prices each research-paid item at the greater of the sponsor’s proposed rate or the site’s charge master rate. That arithmetic cannot happen without both inputs. The protocol-only MCA flags which cells will need INVOICEABLE pricing; it cannot set the price.

Device trials add another layer the protocol-only MCA must handle carefully. When a protocol involves an investigational device, the CMS coverage determination and the IDE approval letter control whether the device and its associated procedures are covered as Category A (experimental, generally not covered) or Category B (non-experimental or investigational, covered when medically necessary). The protocol alone may not tell you which category applies; the IDE approval letter does. Flag the device items in the protocol-only MCA and note that Category A versus B designation is pending the IDE letter. Do not designate them SOC without it.

The Imaging Problem That Templates Cannot Solve

Imaging is the place where protocol-only MCAs fail most reliably, and it is worth spending time here because the error pattern is consistent. A protocol will often specify a scan schedule as a parent rule: CT of the chest, abdomen, and pelvis every eight weeks for nine cycles. That is nine discrete visit events, each of which needs its own cell designation in the visit grid.

What happens in practice is that an MCA template pulls the scan type as a single line item and assigns one designation. The nine-visit schedule collapses into one cell. The result is an MCA that appears to cover imaging but actually designates only one of the nine visits. The other eight scans have no coverage assignment at all when the billing team routes charges.

A worked example makes the stakes concrete. Suppose a Phase II oncology protocol requires CT imaging every eight weeks for nine cycles, and scans one through three are SOC by clinical standard for this disease and line of therapy, while scans four through nine are protocol-required surveillance beyond standard practice and therefore RES. A correct protocol-only MCA produces nine separate cells in the visit grid, with different designations at cycle four. A template that collapses all nine into one line will either overbill Medicare for the RES scans or leave the sponsor budget negotiation without the correct number of research-paid line items. Either error is a compliance exposure. The Rush University Medical Center billing settlement in 2005 established that billing Medicare for items the sponsor had agreed to pay is not a technical error; it is a false claims risk. The fact pattern there involved exactly this kind of misalignment between research cost obligations and insurance billing. Imaging frequency errors reproduce that fact pattern at scale.

Human review of the visit schedule against the protocol schedule of assessments is the only reliable catch for this error. No template reads parent schedules correctly without explicit decomposition by a reviewer who knows to look for it.

What to Flag for the Budget Pass

A protocol-only MCA that is done correctly produces a short, specific handoff document for the budget negotiation. It should identify every cell designated NB/INV that needs charge master pricing, every imaging visit that requires individual designation rather than a collapsed line, every device procedure awaiting IDE letter confirmation, and any visit where the SOC versus RES designation will shift depending on what the sponsor’s budget proposes to pay for. That list is the input the finance team needs to price the budget correctly the first time, rather than discovering misalignments during a monitoring visit or a billing audit two years into the trial.

The protocol-only MCA does not replace the budget reconciliation pass. It makes that pass faster, more accurate, and defensible from day one of site activation.